Corpus ID: 34847509

Ovanon. A new sequential oral contraceptive.

  title={Ovanon. A new sequential oral contraceptive.},
  author={E. Rice-wray and A. Pe{\~n}a and M. Maqueo},
  journal={International journal of fertility},
  volume={13 4},
A clinical study is presented of 122 women who used a new sequential oral contraceptive Ovanon which consists of .08 mg mestranol daily for 7 days followed by 15 days of a combined tablet of .075 mg mestranol and 2.5 mg lynestrenol daily for a total of 1087 cycles. Monthly follow-up clinic visits included patient interviews endometrial biopsies urinalysis prothrombin and coagulation time tests and liver function and steroid excretion tests. Few subjective complaints were recorded among these… Expand
3 Citations

Topics from this paper

A modified sequential contraceptive.
A modified sequential oral contraceptive regimen consisting of 7 days of estrogen-only, followed by 15 days of a combined tablet, presumedly before ovulation, is described, finding that cervical mucus changes considered unfavorable to sperm transport are produced early in the cycle. Expand
Combined clinical, histological and stereomorphometric studies with a new oral contraceptive of normophasic type: Fysioquens.
It is concluded that the abnormal biopsies observed in the beginning of the cycle in some treated patients is due only to a transitory estrogenic effect and that the early administration of progestagen in the normophasic dosage scheme not only counteracts this effect but could play a protective role against hyperplasia. Expand
Assessment of clinical testing methodology.
A review of current clinical testing methodology is made and recommendations call for greater standardization and for the development of new methodology in clinical testing data analysis and research design. Expand